Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists.
about
Medical marijuana: medical necessity versus political agendaEarly somatosensory processing in individuals at risk for developing psychoses.Cannabinoid CB1 Receptor Agonists Do Not Decrease, but may Increase Acoustic Trauma-Induced Tinnitus in RatsEffects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strainReasons for illicit drug use in people with schizophrenia: Qualitative studyCannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research.Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortexAnti-aversive effects of cannabidiol on innate fear-induced behaviors evoked by an ethological model of panic attacks based on a prey vs the wild snake Epicrates cenchria crassus confrontation paradigm.Blurred boundaries: the therapeutics and politics of medical marijuana.Cannabidiol in humans-the quest for therapeutic targetsThe role of 5-HT1A receptors in the anti-aversive effects of cannabidiol on panic attack-like behaviors evoked in the presence of the wild snake Epicrates cenchria crassus (Reptilia, Boidae).Pharmacologic treatment of first-episode schizophrenia: a review of the literatureEndocannabinoid system: potential novel targets for treatment of schizophrenia.Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity.THC and endocannabinoids differentially regulate neuronal activity in the prefrontal cortex and hippocampus in the subchronic PCP model of schizophrenia.Emerging drugs for schizophrenia.Current and future treatment modalities in schizophrenia: novel antipsychotic drugs and cognitive therapy.Evaluation of the insulin releasing and antihyperglycaemic activities of GPR55 lipid agonists using clonal beta-cells, isolated pancreatic islets and miceBeyond dopamine: glutamate as a target for future antipsychotics.Identification of Psychoactive Degradants of Cannabidiol in Simulated Gastric and Physiological Fluid.Pregnenolone blocks cannabinoid-induced acute psychotic-like states in mice.Acute and chronic administration of cannabidiol increases mitochondrial complex and creatine kinase activity in the rat brain.Cannabis use and cognitive functions in at-risk mental state and first episode psychosis.Inhibition of cerebral type 1 cannabinoid receptors is associated with impaired auditory mismatch negativity generation in the ketamine model of schizophrenia.AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.Understanding Patients' Process to Use Medical Marijuana: A Southern New Jersey Community Engagement Project.Endocannabinoids and Schizophrenia.
P2860
Q24633493-C53B1568-E458-4D8B-B57A-BBAC3B36CDFBQ30390556-A6096603-3D18-4F01-8341-C9F0984A2CDAQ30414733-FEFD2728-EBC7-4749-B0BB-A957563D8024Q30442731-952AB534-D281-4DCB-B7AA-4B64A582959CQ33751954-77689EAE-2041-40CF-B08B-67BA20E25522Q33819365-9A735788-8B36-4310-B0C9-5EED0839E484Q34026425-FEA8B468-23F0-48C6-9DD8-310F1BAE69DBQ34028554-7D8FDDBE-6471-4303-8C13-4906B0726191Q34251969-2C9F0878-48CD-42E3-BFC7-EF49D274FD50Q34657897-190DE89B-7138-4166-8E9E-21036687C83AQ34910131-7ECCD739-40EF-448A-991F-988216C88BE9Q35977796-77D15574-83A9-4F8A-9F02-0B302FB215A7Q36675661-C06D0345-9F23-478E-8C58-A2ED75B87970Q37525458-44D1A564-BDDB-4E32-B8F8-A7BD5BAF8BC7Q37597632-FA96B790-35C7-46D8-8664-880F689AA093Q37874626-94D24E4E-297B-4E09-8314-05D0A7D1BC60Q38168861-DF87C066-43EF-41B7-9756-8739702A5C10Q39102543-8A284EB3-3344-4B8E-9990-55C0F1B577DBQ39580232-8C5415E1-F63B-412B-98A7-EB1388A2D672Q41560604-A1F0569D-3674-4A7D-A1A0-A7F9CAFDFDDEQ41994722-838870D0-162D-4BCE-BB10-4638394A4526Q43888192-7DB7B4A4-4A5A-4B8B-9EB7-66A61EBEE53BQ44906174-AAF6FEEA-A2F0-403D-8FC3-AC221CA411C6Q48262695-E78E13A6-C0FA-4EC9-A0C0-17648239527FQ50652493-E6B8D5DF-8658-4446-BFB1-78AFE29BFC60Q53153544-733C3C55-A171-406C-AD49-C0FAFA7CB85FQ55452539-3BB29159-ACAA-4070-9E11-65B9B8073744
P2860
Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists.
@ast
Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists.
@en
Potential antipsychotic properties of central cannabinoid
@nl
type
label
Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists.
@ast
Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists.
@en
Potential antipsychotic properties of central cannabinoid
@nl
prefLabel
Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists.
@ast
Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists.
@en
Potential antipsychotic properties of central cannabinoid
@nl
P2093
P2860
P921
P1476
Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists.
@en
P2093
Franz X Vollenweider
Patrik Roser
Wolfram Kawohl
P2860
P304
P356
10.3109/15622970801908047
P433
P577
2010-03-01T00:00:00Z